IP Library Granted Patent US 7,473,525
Granted Patent B2
US 7,473,525 · App. 10/384,260 · Granted Jan 6, 2009

Compositions and methods for inhibiting expression of anti-apoptotic genes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,473,525
App. No.
10/384,260
Granted
Jan 6, 2009
Kind
B2
Abstract

The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an anti-apoptotic gene, comprising a complementary RNA strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially identical to at least a part of an apoptotic gene, such as a Bcl gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of an anti-apoptotic gene using the pharmaceutical composition; and methods for inhibiting the expression of an anti-apoptotic gene in a cell.

Claims (4)

1. A method for inhibiting the expression of an anti-apoptotic gene in a cell, the method comprising: (a) introducing into the cell in vitro a double-stranded ribonucleic acid (dsRNA), wherein the dsRNA consists of less than 25 nucleotides in length and comprises a complementary RNA strand comprising a complementary nucleotide sequence which is complementary to at least a part of the Bcl-2 gene, and wherein the complementary nucleotide sequence consists of at least 24 nucleotides in length and comprises SEQ ID NO:2; and (b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of the anti-apoptotic gene, thereby inhibiting expression of the Bcl-2 gene in the cell.

2. A method for inhibiting the expression of an anti-apoptotic gene in a cell, the method comprising: (a) introducing into the cell in vitro a double-stranded ribonucleic acid (dsRNA), wherein the dsRNA consists of less than 25 nucleotides in length and comprises a complementary RNA strand comprising a complementary nucleotide sequence which is complementary to at least a part of the Bcl-2 gene, and wherein the complementary nucleotide sequence consists of at least 24 nucleotides in length and comprises SEQ ID NO:4; and (b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of the anti-apoptotic gene, thereby inhibiting expression of the Bcl-2 gene in the cell.

3. The method of claim 1 , wherein the dsRNA further comprises a sense RNA strand, and wherein at least one of the complementary RNA strand or sense RNA strand comprises a nucleotide overhang of 1 to 4 nucleotides in length, and wherein the sense RNA strand comprises the sequence of SEQ ID NO: 1.

4. The method of claim 2 , wherein the dsRNA further comprises a sense RNA strand, and wherein at least one of the complementary RNA strand or sense RNA strand comprises a nucleotide overhang of 1 to 4 nucleotides in length, and wherein the sense RNA strand comprises the sequence of SEQ ID NO:3.

Assignments (4)
SECURITY INTEREST Recorded Oct 1, 2025
From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 072996/0337 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2009
From: ALNYLAM EUROPE AG
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 023070/0300 →
CHANGE OF NAME Recorded Jun 22, 2004
From: RIBOPHARMA AG
To: ALNYLAM EUROPE AG
Reel/Frame 015488/0614 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2003
From: KREUTZER, ROLAND; LIMMER, STEFAN; VORNLOCHER, HANS-PETER; HADWIGER, PHILIPP; GEICK, ANKE; OCKER, MATTHIAS; HEROLD, CHRISTOPH; SCHUPPAN, DETLEF
To: RIBOPHARMA AG
Reel/Frame 014139/0515 →